Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due...
Year: 2024
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and...
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory DiseasesWALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic...
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to...
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of...
Rejuvenation Medical Group of Canada uses MedMatrix AI Reporter to Streamline Reporting and Improve Operations
VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7)...
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem
DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
Four healthy subjects dosed with RECCE® 327 at 3,000mg over 20 minutesData received from this cohort will support preparations for...
Cytek® Biosciences Names William McCombe Chief Financial Officer
Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March...
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer
NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK), a leader in healthcare technology innovation,...
Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024...
Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain
EAACI Congress 2024 EAACI Congress 2024 https://www.globenewswire.com/NewsRoom/AttachmentNg/d32f0dd2-5510-4922-aead-62719b31e294 VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy...
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI...
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors...
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials
ANN ARBOR, Mich., March 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"),...
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell...
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...